Background/Objectives: There is a paucity of
INTRODUCTION
The current standard of care for treating cutaneous melanoma, according to consensus guidelines, is wide local excision with a standard margin of clinically involved skin based on the depth of invasion with the aim of achieving clear margins. 1 Margin examination is performed with vertical bread-loaf sectioning which typically presents less than 1% of the margin for analysis. 2 Mohs micrographic surgery (MMS) allows for a more comprehensive examination of the margins, although is only briefly mentioned in the Clinical Practice Guidelines for the Management of Melanoma in Australia, despite being considered an appropriate use by the American Academy of Dermatology. 3 The use of MMS for melanoma has been reviewed previously by many authors, 4 to which we add the first Australian data and experience.
METHODS AND MATERIALS
In total, 62 patients with 62 lesions of melanoma in situ and lentigo maligna were treated with MMS utilising melanoma-associated antigen recognised by T-cells (MART-1) immunostaining between August 2015 and November 2017. Each lesion had been biopsied and confirmed to be a melanoma.
The procedures were performed under local anaesthesia. The visible extent of the melanoma was identified with clinical assessment (naked eye and dermoscopy) and, typically, an additional 3-mm margin of normal appearing tissue was marked. This debulking layer was excised down to the subcutaneous fat and examined for invasive melanoma using permanent sections. A central slip of tissue from the melanoma was removed to serve as a positive control.
An additional 3 mm of surrounding skin beyond the debulking layer was excised along with the base of the debulking wound to form the Mohs layer, giving a minimum 6-mm excision margin. In sites where tissue conservation was deemed to be critical (such as the nose or eyelid) the debulking layer was reduced to the size of the visible portion of the melanoma. In cases where there was only residual peripheral margin melanoma in situ after attempt at wide local excision, a debulking layer was not excised. The dermoepidermal layer was separated from the fat to allow for 4 lm tissue sectioning that is required for immunohistochemistry. The strips of epidermis and dermis that form the Mohs layer were divided into 2-6 segments, depending on the size of the lesion. All the excised tissue, including the fat layer, was mapped relative to the reference marks. The epidermal and dermal portions of the Mohs layer were mounted as frozen sections as per the usual Mohs tissue processing for nonmelanoma skin cancer. One set was cut for HE staining at the usual 5-8-lm thickness, then mounted onto plain glass slides, and a second set for immunohistochemical staining cut at 4 lm on positive charged slides. MART-1 immunohistochemical staining was used to visualise the melan-A antigen with the protocol detailed in Supplementary Table 1. The fat layer was examined with HE staining alone. The Mohs surgeon examined the prepared slides and marked positive margins on the Mohs map. The criteria used to define a positive margin are detailed in Table 1 . Additional stages (typically 3 mm) were taken from the positive margins until negative margins were achieved. Follow up for recurrence after MMS was performed twice yearly through clinical examination.
RESULTS
A summary of the results is presented in Table 2 . The patients' mean age was 63.2 years (range 34-88 years) with a slight female (33/62, 53%) predominance. 94% of the lesions were primary and 6% were locally recurrent. 29% (18/62) of melanomas were referred for treatment after being incompletely excised with attempt at wide local excision. Eight of these melanomas had an invasive component with an average Breslow depth of 0.5mm (range 0.25À1.8mm) however only the residual melanoma in situ component was treated with MMS. Most lesions were on the face (79%) with 5% on the neck, 5% on the scalp and 11% involving the trunk or limbs. The mean tumour diameter was 2.01 cm and the mean defect diameter post-MMS was 3.32 cm. The mean clinical excision margin was 6.7mm however, we believe this to be an underestimate given the initial margin in 18 of the incompletely excised lesions was not known with certainty. 19% of lesions were cleared with 3-mm clinical margins, 68% with 6 mm, 92% with 9 mm and 100% with 12-mm. Of the 22 lesions that were initially given a 3-mm clinical margin, 10/22 (45%) required an extra stage. The size of the clinical surgical margin needed to remove the melanoma was related to tumour diameter, with all tumours larger than 2.2 cm requiring margins of 9 mm or more for clearance. Recurrent tumours required an average 9-mm clinical margin for clearance. 66% of lesions were excised with one stage, 26% with two stages and 8% required three stages for clearance. No debulking specimens contained invasive melanoma. Follow up ranged from 3 to 30 months with no reported recurrences or melanoma-related deaths.
DISCUSSION
Our low recurrence rate is consistent with the literature. Most authors report recurrence rates lower than 2% and survival rates equal to or better than that achieved using a wide local excision [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] (Table 3 ). The average clinical excision margin of 6.7 mm is slightly less than the 7.2 mm margin reported in the largest North American series. 5, 12 This finding is important, given that the current Australian melanoma guidelines recommend 5-mm clinical excision margins for melanoma in situ and lentigo maligna. 1 If 5-mm clinical margins had been taken in our case series, an incomplete excision rate of around 30% would be expected. 1 In our series, 32% of lesions required clinical margins more than 6 mm for clearance with large (more than 2.2 cm in diameter) tumours requiring at least 9-mm margins and recurrent tumours requiring 9-mm margins on average. This information may be of benefit to dermatological surgeons when planning melanoma excisions.
Compared with the study on the use of MMS for melanoma published by Valent ın-Nogueras and colleagues, 5 there was little difference in the patients' average age, lesion site and type. Our mean tumour diameter was slightly larger at 2.0 cm compared with 1.6 cm. We cleared 68% of lesions with clinical margins of 6 mm compared with 82%. Our first stage clearance rate was lower, with 66% compared with 76%.
Our series suggests there is a potential tissue-conserving benefit with MMS. Of the lesions we attempted to excise with a 3-mm margin, 55% were cleared. The high incomplete excision rate that would be expected when attempting this strategy with wide local excision would preclude its use.
We found MART-1 immunostaining to be an important adjuvant to frozen section analysis with Hematoxylin and Eosin (HE). In Fig. 1 we contrast fresh frozen sections of melanoma with MART-1 stained sections to illustrate the difficulty of interpretation with frozen sections alone. There is debate in the literature as to the preferred immunostain for melanoma. 17 MART-1 has been the most popular however SOX-10 and microphthalmia associated transcription factor are prominising alternatives as their nuclear staining pattern may simplify melanocyte identification. 17, 18 Desmoplastic or spindle cell melanomas are notable exceptions, with S100 or SOX-10 being better in these scenarios. 18 Mel-5 has been favoured by one institution and is supported by their low recurrence rates. 15 We noted are number of challenges when interpreting melanoma pathology specimens. Firstly, it is not uncommon to see mild to moderate melanocyte confluence (six or fewer adjacent melanocytes) 19, 20 in chronic sundamaged skin, which can be misinterpreted as melanoma. These findings, along with single cell atypia, focal pagetosis and cryotherapy artefact with frozen sections have all been noted by previous authors. 19, 20 Potential strategies to distinguish melanocytic hyperplasia from lentigo maligna include using a negative control of distant perilesional skin or taking a sample of the melanoma as a positive control for comparison. We found it helpful to discuss and review cases with two experienced dermatopathologists to get differing perspectives on interpretation. Another challenge is avoiding false positive interpretations with MART-1 sections. Given it is a cytoplasmic stain, melanosome binding in melanocyte dendrites can give the false impression of pagetoid spread or increased melanocyte numbers. This can be particularly problematic when sections are slightly cross cut (Fig. 2) . Overstaining of MART-1 in the presence of lichenoid inflammation, pigmented solar keratoses and solar lentigo needs to be considered and identified. 21 Given we used a manual process for MART-1 immunostaining, there were occasional issues with understaining that needed to be identified and addressed. Our case series focused on the treatment of melanoma in situ and lentigo maligna, given concerns that invasive melanoma has a propensity for discontinuous growth. 22 Whilst there were 8 lesions treated that had a component of invasive melanoma, this was already known to be clear post wide local excision and only the residual peripheral margin melanoma in situ was treated with MMS. It should be acknowledged, however, that there are published reports supporting the use of MMS for invasive melanoma, citing local recurrence and melanoma survival rates as equal to or better than wide local excision. 22 There are theoretical concerns about not knowing the histological clearance margin after MMS, with one study concluding a higher recurrence rate can be expected after a wide local excision when histological margins of less than 8 mm are achieved. 23 It is difficult to comment on this further, given that the recurrence rates with MMS have been equal to or better than wide local excision.
Critics have argued that MMS is not cost-effective when factoring in supply costs, time and technician wages as a proportion of reimbursement, and this has been addressed in depth previously. 24 In specific reference to melanoma, the main source of extra cost is staff wages because of the average 1.5-h turnaround time for an immunohistochemical case. The other point of difference is that when a debulking specimen is taken there are additional costs for the permanent sections as Medicare in Australia does not reimburse the cost of external pathology on a MMS case.
The main limitation of the study is the short duration of follow up and small case numbers by international comparison. Despite this, we add the first Australian data to the literature and provide an Australian perspective on the technique. We hope more local data will be forthcoming as Mohs surgeons consider gaining experience in treating lentigo maligna and melanoma in situ with MMS. 
